Orient Europharma (4120) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 友華

Orient Europharma (4120) reported revenue of NT$419.8 million for Oct 2026, -4.2% year on year and -3.6% from the previous month. Revenue for Jan–Oct 2026 was NT$3.95 billion (+3.0% year on year).

In Oct 2026, it ranked No. 22 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$385.9 million24/10Nov 2024 NT$399.8 millionDec 2024 NT$338.4 millionJan 2025 NT$426.7 millionFeb 2025 NT$357.9 million25/02Mar 2025 NT$371.6 millionApr 2025 NT$375.9 millionMay 2025 NT$392.2 millionJun 2025 NT$358.1 million25/06Jul 2025 NT$349.3 millionAug 2025 NT$370.2 millionSep 2025 NT$395.7 millionOct 2025 NT$438.1 million25/10Nov 2025 NT$370.7 millionDec 2025 NT$387.2 millionJan 2026 NT$445.5 millionFeb 2026 NT$304.5 million26/02Mar 2026 NT$399 millionApr 2026 NT$395.3 millionMay 2026 NT$348.8 millionJun 2026 NT$448 million26/06Jul 2026 NT$395.8 millionAug 2026 NT$358.9 millionSep 2026 NT$435.3 millionOct 2026 NT$419.8 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$419.8 million-4.2%-3.6%
Sep 2026NT$435.3 million+10.0%+21.3%
Aug 2026NT$358.9 million-3.1%-9.3%
Jul 2026NT$395.8 million+13.3%-11.7%
Jun 2026NT$448 million+25.1%+28.4%
May 2026NT$348.8 million-11.0%-11.8%
Apr 2026NT$395.3 million+5.2%-0.9%
Mar 2026NT$399 million+7.4%+31.1%
Feb 2026NT$304.5 million-14.9%-31.6%
Jan 2026NT$445.5 million+4.4%+15.0%
Dec 2025NT$387.2 million+14.4%+4.5%
Nov 2025NT$370.7 million-7.3%-15.4%
Oct 2025NT$438.1 million+13.5%+10.7%
Sep 2025NT$395.7 million+17.0%+6.9%
Aug 2025NT$370.2 million-2.2%+6.0%
Jul 2025NT$349.3 million-0.9%-2.5%
Jun 2025NT$358.1 million+3.4%-8.7%
May 2025NT$392.2 million+11.0%+4.3%
Apr 2025NT$375.9 million-2.2%+1.2%
Mar 2025NT$371.6 million+10.3%+3.8%
Feb 2025NT$357.9 million+10.3%-16.1%
Jan 2025NT$426.7 million-3.6%+26.1%
Dec 2024NT$338.4 million-15.8%-15.4%
Nov 2024NT$399.8 million-3.0%+3.6%
Oct 2024NT$385.9 million+0.3%+14.1%

Jan–Oct 2026 cumulative: NT$3.95 billion (+3.0% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Orient Europharma vs PEC / Orient Europharma vs Lotus Pharm / Orient Europharma vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16